60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) and Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.
Profitability
This table compares 60 Degrees Pharmaceuticals and Eyepoint Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 60 Degrees Pharmaceuticals | -650.21% | N/A | -136.81% |
| Eyepoint Pharmaceuticals | -10,994.73% | -135.81% | -108.35% |
Analyst Ratings
This is a summary of recent ratings and target prices for 60 Degrees Pharmaceuticals and Eyepoint Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 60 Degrees Pharmaceuticals | 1 | 2 | 1 | 0 | 2.00 |
| Eyepoint Pharmaceuticals | 1 | 6 | 4 | 0 | 2.27 |
60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 1,519.13%. Eyepoint Pharmaceuticals has a consensus price target of $25.70, indicating a potential upside of 759.53%. Given 60 Degrees Pharmaceuticals’ higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Eyepoint Pharmaceuticals.
Insider & Institutional Ownership
8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares 60 Degrees Pharmaceuticals and Eyepoint Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 60 Degrees Pharmaceuticals | $1.11 million | 2.71 | -$7.36 million | ($4.82) | -0.18 |
| Eyepoint Pharmaceuticals | $2.79 million | 92.46 | -$231.96 million | ($3.74) | -0.80 |
60 Degrees Pharmaceuticals has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
60 Degrees Pharmaceuticals has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.
Summary
Eyepoint Pharmaceuticals beats 60 Degrees Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
